Webinar

Trends in Clinical Oncology

Part I: Antibody Drug Conjugates: Evolution, Clinical Successes, and Next-Generation Designs

Thursday, October 15, 2026 | 11:00am EST | 8:00am PST

Antibody–drug conjugates (ADCs) have advanced from early, heterogeneous cytotoxic delivery systems into highly engineered therapeutic platforms. This webinar will review the scientific and clinical evolution of ADCs, from first-generation constructs with unstable linkers and variable drug-to-antibody ratios to modern designs featuring optimized conjugation, cleavable linkers, potent payloads, and controlled bystander activity.

The session will highlight key determinants of ADC performance and examine clinically validated successes and emerging strategies to improve therapeutic index, as well as evaluate mechanisms of resistance and causes of toxicity.

What you will learn:

How ADCs have evolved from early cytotoxic delivery systems to next-generation therapeutic platforms with improved design and clinical utility.
Which biological and pharmacologic factors influence ADC performance, including target expression, linker stability, payload properties, drug-to-antibody ratio, and tumor heterogeneity.
What emerging strategies are being used to improve efficacy, manage toxicity, address resistance, and expand the therapeutic potential of ADCs in oncology.

Part II: Glues and degrader therapeutics: evolution, clinical successes, and next-generation designs

Thursday, November 12, 2026

Part III: Metabolic-targeting therapeutics: evolution, clinical successes, and next-generation designs

Thursday, December 10, 2026

Part IV: Cell-cycle inhibitor therapeutics: evolution, clinical successes, and next-generation designs

Thursday, January 14, 2027

Speakers

Maria Prendes, Ph.D.

Head of Scientific Affairs, NeoGenomics Laboratories, Inc.

NeoGenomics

Maria J. Prendes, Ph.D., is an experienced oncology translational and clinical medicine expert with a strong track record of advancing biomarker-driven strategies in clinical drug development. She currently serves as Head of Scientific Affairs at NeoGenomics, where she collaborates with global biopharma partners to design and implement biomarker strategies that support precision medicine and clinical trial innovation. Over the course of her career, Dr. Prendes has contributed to scientific leadership to nearly 4,000 clinical oncology development programs, offering extensive expertise across molecular diagnostics, digital pathology, and companion diagnostic disciplines. An inventor on 49 patents and author of multiple scientific publications and white papers, she is recognized for translating complex biomarker science into actionable strategies that accelerate oncology drug development.

Register here!

Already registered? Click here to login.